Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1982 2
1989 1
1990 1
1991 1
1996 1
1997 1
1998 3
1999 3
2000 2
2001 2
2002 2
2003 1
2004 2
2005 5
2006 2
2007 3
2008 2
2009 11
2010 10
2011 11
2012 14
2013 25
2014 17
2015 17
2016 9
2017 21
2018 6
2019 5
2020 4
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 24038559

162 results
Results by year
Filters applied: . Clear all
Page 1
Living kidney transplantation in adult patients with atypical haemolytic uraemic syndrome.
Verhave JC, Westra D, van Hamersvelt HW, van Helden M, van de Kar NC, Wetzels JF. Verhave JC, et al. Neth J Med. 2013 Sep;71(7):342-7. Neth J Med. 2013. PMID: 24038559 Free article.
Kidney transplantation in atypical haemolytic uraemic syndrome (aHUS): a cheap way out?
Bemelman FJ, ten Berge IJ. Bemelman FJ, et al. Neth J Med. 2013 Sep;71(7):339-41. Neth J Med. 2013. PMID: 24038558 Free article. No abstract available.
Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.
Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP. Xie L, et al. Transplant Proc. 2012 Dec;44(10):3037-40. doi: 10.1016/j.transproceed.2012.07.141. Transplant Proc. 2012. PMID: 23195022
Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
Duineveld C, Verhave JC, Berger SP, van de Kar NCAJ, Wetzels JFM. Duineveld C, et al. Am J Kidney Dis. 2017 Dec;70(6):770-777. doi: 10.1053/j.ajkd.2017.06.024. Epub 2017 Aug 16. Am J Kidney Dis. 2017. PMID: 28821363
Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
Yamamoto T, Watarai Y, Futamura K, Okada M, Tsujita M, Hiramitsu T, Goto N, Narumi S, Takeda A, Kobayashi T. Yamamoto T, et al. Transplant Proc. 2017 Jan-Feb;49(1):159-162. doi: 10.1016/j.transproceed.2016.10.013. Transplant Proc. 2017. PMID: 28104125
Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy.
Zlamy M, Hofer J, Elias J, Vogel U, Frosch M, Jungraithmayr T, Zimmerhackl LB, Prelog M. Zlamy M, et al. Pediatr Transplant. 2012 Sep;16(6):E246-50. doi: 10.1111/j.1399-3046.2011.01585.x. Epub 2011 Oct 4. Pediatr Transplant. 2012. PMID: 21967634
Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome.
Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S. Weitz M, et al. Pediatr Nephrol. 2011 Aug;26(8):1325-9. doi: 10.1007/s00467-011-1879-9. Epub 2011 May 10. Pediatr Nephrol. 2011. PMID: 21556717
Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.
Okumi M, Tanabe K. Okumi M, et al. Nephrology (Carlton). 2016 Jul;21 Suppl 1:9-13. doi: 10.1111/nep.12776. Nephrology (Carlton). 2016. PMID: 26988663 Review.
[De novo hemolytic uremic syndrome in a kidney-pancreas recipient in the postoperative period].
Gutiérrez de la Fuente C, Sola E, Alférez MJ, Navarro A, Cabello M, Burgos D, González Molina M. Gutiérrez de la Fuente C, et al. Nefrologia. 2004;24 Suppl 3:3-6. Nefrologia. 2004. PMID: 15219059 Free article. Spanish.
Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N. Mallett A, et al. Intern Med J. 2015 Oct;45(10):1054-65. doi: 10.1111/imj.12864. Intern Med J. 2015. PMID: 26247170
162 results
Jump to page
Feedback